University of Maryland School of Dentistry
Microbiology and Immunology
Dr. Paul and Mrs. Jean Corcoran Endowed Professor and Chair, Department of Microbial Pathogenesis, School of Dentistry, Distinguished University Professor
School of Dentistry, 9215
Education and Training
Postdoctoral Fellowship, 1997-2002, Department of Medicine and Microbiology, University of Washington, Seattle, WA. Advisor: Dr. Samuel I. Miller
Postdoctoral Fellowship. 1996-1997, Myles H. Thaler Center for Retrovirus Research. Miles H. Thaler Post-Doctoral Fellow. Department of Microbiology. University of Virginia, Charlottesville, VA. Advisor: Drs. Marie-Louise Hammarskjöld and David Rekosh
Ph.D., 1996, University of Virginia, Charlottesville, Virginia. Advisor: Dr. Marie-Louise Hammarskjöld. Major - Microbiology
M.A., 1988, State University of New York at Buffalo, Buffalo, New York. Advisor: Dr. Joseph M. Merrick. Major - Microbiology
B.S., State University of New York at Oswego, Oswego, New York. Major –Microbiology/Chemistry
Robert (Bob) K. Ernst, PhD, is the Dr. Paul and Mrs. Jean Corcoran Endowed Professor and Chair of the Department of Microbial Pathogenesis at the University of Maryland, Chair of the Department of Microbial Pathogenesis in the School of Dentistry, an Adjunct Professor in the Department of Microbiology and Immunology at the UM School of Medicine, and a UMB Distinguished University Professor.
- O'Meara TR, Nanishi E, McGrath ME, Barman S, Dong D, Dillen C, Menon M, Seo HS, Dhe-Paganon S, Ernst RK, Levy O, Frieman MB, Dowling DJ. (2023) Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance. J Allergy Clin Immunol. PMID: 37595760
- Hu G, Varisco DJ, Das S, Middaugh CR, Gardner F, Ernst RK, Picking WL, Picking WD. (2023) Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists. Heliyon. PMID: 37483830
- Smith RD, Johnson JK, Ernst RK. (2023) Comparison of 3 diagnostic platforms for identification of bacteria and yeast from positive blood culture bottles. Diagn Microbiol Infect Dis. PMID: 37478505
- Das S, Howlader DR, Lu T, Whittier SK, Hu G, Sharma S, Dietz ZK, Ratnakaram SSK, Varisco DJ, Ernst RK, Picking WD, Picking WL. (2023) Immunogenicity and protective efficacy of nanoparticle formulations of L-SseB against Salmonella Front Immunol. PMID: 37457702
- Lee KS, Rader NA, Miller-Stump OA, Cooper M, Wong TY, Shahrier Amin M, Barbier M, Bevere JR, Ernst RK, Heath Damron F. (2023) Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice. Vaccine. PMID: 37407405
- Chandler CE, Hofstaedter CE, Hazen TH, Rasko DA, Ernst RK. (2023) Genomic and Functional Characterization of Longitudinal Pseudomonas aeruginosa Isolates from Young Patients with Cystic Fibrosis. Microbiol Spectr. PMID: 37358436
- Pětrošová H, Mikhael A, Culos S, Giraud-Gatineau A, Gomez AM, Sherman ME, Ernst RK, Cameron CE, Picardeau M, Goodlett DR. Front Microbiol. (2023) Lipid A structural diversity among members of the genus Leptospira. Front Micro. PMID: 37303810
- Yang H, Sherman ME, Koo CJ, Treaster LM, Smith JP, Gallaher SG, Goodlett DR, Sweet CR, and Ernst RK. (2023) Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions. J Am Soc Mass Spectrom. Accepted for publication May 15. PMID: 37184080
- Marrujo SA, Hubble VB, Yang J, Wang M, Nemeth AM, Barlock SL, Juarez D, Smith RD, Melander RJ, Ernst RK, Chang M, Melander C (2023) Dimeric 2-aminoimidazoles are highly active adjuvants for gram-positive selective antibiotics against Acinetobacter baumannii. Eur J Med Chem. PMID: 37023677
- Howlader DR, Das S, Lu T, Mandal RS, Hu G, Varisco DJ, Dietz ZK, Ratnakaram SSK, Ernst RK, Picking WD, Picking WL (2023) A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection. NPJ Vaccines. PMID: 36918600
Complete List of Published Work in My Bibliography (ORCID 0000-0001-5016-8694): http://www.ncbi.nlm.nih.gov/pubmed?term=ernst+r+k
The focus of my laboratory is to understand the molecular basis by which bacteria (Gram-negative and positive) modify the lipid component of their membrane and how these alterations affect or circumvent normal host innate immune system responses. These modifications can promote resistance to host innate immune killing mechanisms by antimicrobial compounds and alter recognition by TLR4. To the end, I have extensive experience in the discovery and analysis of various structural modification of lipopolysaccharide (LPS), the major component of the Gram-negative bacterial envelope and lipoteichoic acid (LTA), the major component of the Gram-positive bacterial. In addition, we have been using a variety of infection routes (aerosol, subcutaneous, IP) to determine the role of the host innate and adaptive immune systems in the control of mutant strains with defects in enzymes required for lipid biosynthesis. We are utilizing mass spectrometry, gas chromatography, and bioinformatics to identify genes required for lipid biosynthesis and their interactions with the host innate immune system, specifically components of the TLR4 complex.
Additionally, I serve as the Co-Director of the recently established Spatial Systems Biology Laboratory (SSBL), a spatial ‘omics imaging biocontainment suite for workflows developed specifically for a variety of BSL-2, BSL-3, and select agent BSL-3 pathogen models at the University of Maryland School of Dentistry. We are currently developing a novel lipidomic approach for rapidly identifying bacterial and fungal organisms directly from urine, blood, BAL fluid without the need for culture and an associated machine learning/AI software package that can be used to automatically identify organisms directly from mass spectrum. We have also commenced a large-scale surveillance project to identify microorganisms from the Chesapeake Bay that grow at reduced temperatures using lipidomics, where these results will be combined with sequence metagenomics of bulk water samples and 16S sequencing of individual organisms with researchers at the US Naval Academy. Finally, through the characterization of lipid A biosynthetic enzymes, we have developed unique TR4 agonists that are currently being developed as vaccine adjuvants.
|2021||University System of Maryland – Regents Award – Excellence in Research|
|2020||Dr. Paul and Mrs. Jean Corcoran Endowed Professorship|
|2019||Entrepreneur of the Year, University of Maryland – Baltimore|
|2018||Dr. Mark E Shirtliff PhD Student Mentor Award, University of Maryland - Baltimore|
|2017||Researcher of the Year, University of Maryland – Baltimore|
|2016||Maryland Department of Commerce Life Award –UMB-JHU Pataigin – Lipid-based microbial diagnostic platform|
|2016||Maryland-John Hopkins Alliance Ventures award – Anti-sepsis therapeutics|
|2014||Maryland-John Hopkins Alliance Ventures award – Lipid-based bacterial diagnostic platform|
|2006||Philip and Helen Fialkow Scholar Award, Outstanding Assistant Professor, School of Medicine, University of Washington|
Contract, NIH/NIAID (PI): Adjuvant development of the TLR4 ligand BECC470s (2023-2028) Develop the adjuvant potential of BECC470s through IND-enabling studies.
R21, NIH/NIAID (MPI): Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress (2023-2025) Use spatial metabolomics and lipid A mapping to correlate the relationship between Pa lipid A and the host lung response.
R43, NIH/NIAID (subcontract): Rapid Microbial ID Direct from Specimen (2023-2024) Develop a prototype clinical assay to evaluate clinical specimens for identification of pathogens using MS without ex vivo growth.
R01, NIH/NIAID (Co-I): Structural determinants of activity and mechanism of cationic peptide antibiotic activity against colistin-resistant bacteria (2023-2028) Determine how resistance patterns of levels of colistin resistance correlate with the quantities of amino-containing moieties in lipid A.
Cystic Fibrosis Foundation (PI): Characterization of airway responses to adaptive P. aeruginosa lipid A structural variants in CF (2023-2025) Determine the prevalence of specific lipid A biosynthetic enzyme alterations in a diverse cohort of clinical Pa isolates and evaluate the host response.
R01, NIH/NIAID (Co-I): A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa (2022-2027) Develop a prophylactic vaccine using the BECC adjuvant system to prevent initial colonization by P. aeruginosa.
R01, NIH/NIAID (Co-I): Repurposing Gram-Positive Antibiotics for Gram-negative Bacteria using Antibiotic Adjuvants (2022-2027) Elucidate specific changes in the structure of lipid A A. baumannii to determine the effect of the novel compounds to specifically downregulate LPS alterations.
DOD, (Co-I): Pain and the Immune System: A Novel Therapeutic Approach (2021-2025) Examine altering the host innate immune response in treating chronic pain.
R21, NIH/NIA (Co-I): Preventing Alzheimer's Disease with Designer Lipids (2021-2023) Determine the compatibility of a probiotic strain with long-term gut colonization in a mouse model of Alzheimer’s disease.
R01, NIH/NIDCR (Co-I): Novel Target Identification for Treatment of Chronic Overlapping Pain Using Multimodal Brain Imaging (2020-2024) Determine novel biomarkers and therapeutic targets for chronic overlapping pain conditions.
R01, NIH/NIAID (MPI): Colistin resistance in extensively drug-resistant Gram-negative pathogens (2020-2025) Develop quantitative test for colistin resistance that is clinically applicable and elucidate remodeling of lipid A.
R01, NIH/NIAID (MPI): MS diagnostic bacterial identification library (2020-2025) Establish a rapid, small scale extraction procedure for lipids isolated from bacterial and fungal pathogens.
DOD, (PI): Novel Live Vaccines with Modified Lipid A for the Prevention of Shigella Diarrheal Disease (2019-2023 NCE) Engineer and evaluate live attenuated Shigella subspecies vaccines with alterations in lipid A molecule for use as a live oral vaccine.
Contract, NIH/NIAID (PI): Adjuvant development of the TLR4 ligand, BECC438 (2018-2023 NCE) Develop the adjuvant potential of BECC438 through IND-enabling studies.
R01, NIH/NIAID (Co-I): Development of Antibiotic Adjuvants for Gram-Negative Bacteria (2018-2023 NCE) Elucidate changes in the structure of lipid A to novel small molecule antimicrobial.